MedKoo Biosciences/Lapatinib ditosylate/100946/100g

RelatedCAS#:388082-77-7(ditosylate) 231277-92-2(freebase)  

Synonym:GSK572016;GSK-572016;GSK572016;GW2016;GW-2016;GW2016;Lapatinib;Lapatinibditosylate;Brandname:Tykerb.CAT#100490B.

IUPAC/ChemicalName:N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amineditosylate

InChiKey:UWYXLGUQQFPJRI-UHFFFAOYSA-N

InChiCode:InChI=1S/C29H26ClFN4O4S.2C7H8O3S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19;2*1-6-2-4-7(5-3-6)11(8,9)10/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35);2*2-5H,1H3,(H,8,9,10)

SMILESCode:O=S(CCNCC1=CC=C(C2=CC3=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)N=CN=C3C=C2)O1)(C)=O.OS(=O)(C6=CC=C(C)C=C6)=O.OS(=O)(C7=CC=C(C)C=C7)=O

TechnicalData

AdditionalInformation

Note:Previouslyweassigned100490BforLapatinibditosylate.
Newcatalogue#forLapatinibditosylatis100946,whichwascreatedon2/10/2017.
CAT#100490BisthesameproductasCAT#100946.

References

1:BowenJM.Developmentoftheratmodeloflapatinib-induceddiarrhoea.Scientifica(Cairo).2014;2014:194185.doi:10.1155/2014/194185.Epub2014Jul7.Review.PubMedPMID:25126444;PubMedCentralPMCID:PMC4121095.

2:WangH.LapatinibforthetreatmentofbreastcancerinthePeople'sRepublicofChina.OncoTargetsTher.2014Jul31;7:1367-73.doi:10.2147/OTT.S60586.eCollection2014.Review.PubMedPMID:25114575;PubMedCentralPMCID:PMC4125370.

3:Abdel-RahmanO,FouadM.Doestheuseoflapatinibincreasetheriskoffatigueandhepatictoxicitiesinpatientswithsolidtumors?Acriticalliteraturereviewandmeta-analysis.ExpertOpinDrugSaf.2014Aug;13(8):999-1008.doi:10.1517/14740338.2014.921679.Epub2014Jun14.Review.PubMedPMID:24930544.

4:NoltingM,Schneider-MerckT,TrepelM.Lapatinib.RecentResultsCancerRes.2014;201:125-43.doi:10.1007/978-3-642-54490-3_7.Review.PubMedPMID:24756789.

5:GandhiMD,AgulnikM.Targetedtreatmentofheadandnecksquamous-cellcarcinoma:potentialoflapatinib.OncoTargetsTher.2014Feb13;7:245-51.doi:10.2147/OTT.S46933.eCollection2014.Review.PubMedPMID:24611017;PubMedCentralPMCID:PMC3928467.

6:BianchiGV,DucaM,SicaL,MarianiG.Metastaticbreastcancertreatedwithlapatinibwithaprolongedbenefit:acasereportandareviewoftherapeuticoptionsavailable.Tumori.2013Nov-Dec;99(6):269e-72e.doi:10.1700/1390.15466.Review.PubMedPMID:24503801.

7:BotrelTE,PaladiniL,ClarkOA.Lapatinibpluschemotherapyorendocrinetherapy(CET)versusCETaloneinthetreatmentofHER-2-overexpressinglocallyadvancedormetastaticbreastcancer:systematicreviewandmeta-analysis.CoreEvid.2013;8:69-78.doi:10.2147/CE.S50474.Epub2013Sep30.Review.PubMedPMID:24115917;PubMedCentralPMCID:PMC3793631.

8:LarsenPB,KümlerI,NielsenDL.AsystematicreviewoftrastuzumabandlapatinibinthetreatmentofwomenwithbrainmetastasesfromHER2-positivebreastcancer.CancerTreatRev.2013Nov;39(7):720-7.doi:10.1016/j.ctrv.2013.01.006.Epub2013Mar5.Review.PubMedPMID:23481218.

9:Gross-GoupilM,BernhardJC,RavaudA.Lapatinibandrenalcellcarcinoma.ExpertOpinInvestigDrugs.2012Nov;21(11):1727-32.doi:10.1517/13543784.2012.713935.Epub2012Aug9.Review.PubMedPMID:22876762.

10:RiemsmaR,ForbesCA,AmonkarMM,LykopoulosK,DiazJR,KleijnenJ,ReaDW.Systematicreviewoflapatinibincombinationwithletrozolecomparedwithotherfirst-linetreatmentsforhormonereceptorpositive(HR+)andHER2+advancedormetastaticbreastcancer(MBC).CurrMedResOpin.2012Aug;28(8):1263-79.doi:10.1185/03007995.2012.707643.Epub2012Jul16.Review.PubMedPMID:22738819.

11:OpdamFL,GuchelaarHJ,BeijnenJH,SchellensJH.Lapatinibforadvancedormetastaticbreastcancer.Oncologist.2012;17(4):536-42.doi:10.1634/theoncologist.2011-0461.Epub2012Apr3.Review.PubMedPMID:22477724;PubMedCentralPMCID:PMC3336826.

12:HurvitzSA,KakkarR.RoleoflapatinibaloneorincombinationinthetreatmentofHER2-positivebreastcancer.BreastCancer(DoveMedPress).2012Apr3;4:35-51.doi:10.2147/BCTT.S29996.Review.PubMedPMID:24367193;PubMedCentralPMCID:PMC3846547.

13:FleemanN,BagustA,BolandA,DicksonR,DundarY,MoonanM,OyeeJ,BlundellM,DavisH,ArmstrongA,ThorpN.Lapatinibandtrastuzumabincombinationwithanaromataseinhibitorforthefirst-linetreatmentofmetastatichormonereceptor-positivebreastcancerwhichover-expresseshumanepidermalgrowthfactor2(HER2):asystematicreviewandeconomicanalysis.HealthTechnolAssess.2011;15(42):1-93,iii-iv.doi:10.3310/hta15420.Review.PubMedPMID:22152751.

14:VrdoljakE,BobanM,BanM.LapatinibinthetreatmentofHER-2overexpressingbreastcancer.JBUON.2011Jul-Sep;16(3):393-9.Review.PubMedPMID:22006739.

15:KennyLM,LamEW.Review:lapatinibinmetastaticcolorectalcancer-anotherstrategyfordiseasecontrol?ClinAdvHematolOncol.2011Jun;9(6):500-1.Review.PubMedPMID:21841752.

16:BouchalovaK,CizkovaM,CwiertkaK,TrojanecR,FriedeckyD,HajduchM.Lapatinibinbreastcancer-thepredictivesignificanceofHER1(EGFR),HER2,PTENandPIK3CAgenesandlapatinibplasmalevelassessment.BiomedPapMedFacUnivPalackyOlomoucCzechRepub.2010Dec;154(4):281-8.Review.PubMedPMID:21293538.

17:MerriamP,SikovWM.Clinicalutilityofthecombinationoflapatinibandletrozoleinthemanagementofhormonereceptor-positiveandHER2-positiveadvancedbreastcancer.BreastCancer(DoveMedPress).2011Oct26;3:139-50.doi:10.2147/BCTT.S12150.Review.PubMedPMID:24367183;PubMedCentralPMCID:PMC3846896.

18:GiampagliaM,ChiuriVE,TinelliA,DeLaurentiisM,SilvestrisN,LorussoV.Lapatinibinbreastcancer:clinicalexperiencesandfutureperspectives.CancerTreatRev.2010Nov;36Suppl3:S72-9.doi:10.1016/S0305-7372(10)70024-4.Review.PubMedPMID:21129615.

19:MacFarlaneRJ,GelmonKA.Lapatinibforbreastcancer:areviewofthecurrentliterature.ExpertOpinDrugSaf.2011Jan;10(1):109-21.doi:10.1517/14740338.2011.533168.Epub2010Nov20.Review.PubMedPMID:21091041.

20:AraiH,YamakiM,NishimuraY.[Pharmacologicalprofilesandclinicaleffectsoflapatinibtosilate(Tykerb)].NihonYakurigakuZasshi.2010Sep;136(3):175-84.Review.Japanese.PubMedPMID:20838021.